Loading…
← CockpitCompetitor Analysis › 301277.SZ Newland Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Newland Pharmaceutical Co., Ltd. Class A301277.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 36
Mkt cap
$488M
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$3.63M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+4.9 pp
WACC 6.6%
Hurdle
-0 pp
Req g minus delivered
Close · CNYCN¥8.35
1D-2.0%
1W-6.7%
1M-15.5%
3M-23.5%
6M-22.5%
YTD-29.2%
1Y-36.5%
ATR %3.5%
52w lowhigh39.7% off high

What Newland Pharmaceutical does

Employees: 981

Newland Pharmaceutical at a glance

Size Newland Pharmaceutical (301277.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $488M, the 3754th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.35 on 18 Nov 2026.

Performance Over six months the shares fell 22.5%, against -13.3% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 9.4% over the last twelve months (peer median +12.8%); the operating margin is 11.5% (peer median 8.4%).

Valuation It trades at 3.5× enterprise value to sales against a peer median of 4.2× (9th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -0 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.9 points above its cost of capital (6.6% WACC).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 86301277.SZ 78
Six months, rebased to 100: Newland Pharmaceutical against the median of its 20 peers (local-currency closes).

Newland Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥734MCN¥670MCN¥724MCN¥648MCN¥624M
Revenue growth—-7%+12%+4%—
Gross profitCN¥243MCN¥210MCN¥269MCN¥242MCN¥210M
EBITDAn/aCN¥177MCN¥221MCN¥194MCN¥170M
Net incomeCN¥93.0MCN¥121MCN¥174MCN¥159MCN¥132M
Free cash flowCN¥41.6MCN¥25.8MCN¥30.2MCN¥181MCN¥8.84M
Capital expenditureCN¥36.8MCN¥101MCN¥111MCN¥96.5MCN¥74.3M
Total debtCN¥3.73MCN¥5.69MCN¥3.83MCN¥2.72MCN¥17.0M

Quarterly statements and history in the cockpit →

Newland Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%3005840030201666002107AARTIDRUGS688373003090600513TKNORGNX600222HNSA600624SMSPHARMAGYREAQST3705GUJTHEM301201301277.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Newland Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×10×20×3005840030201666002107AARTIDRUGS688373003090600513TKNO600222HNSA600624SMSPHARMAGYREAQST603207GUJTHEM301201301277.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Newland Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%3005841666002107AARTIDRUGS600222HNSA301277.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Newland Pharmaceutical is the large dot.

Newland Pharmaceutical competitors and peer comparison

How Newland Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Newland Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure301277.SZPeer medianRank in peer set
1-month return-15.5%-2.6%4th lowest of 21
6-month return-22.5%-13.3%6th lowest of 21
Distance from 52-week high-39.7%-35.5%9th lowest of 21
Revenue growth (TTM)+9.4%+12.8%9th lowest of 21
Operating margin11.5%8.4%8th highest of 21
EV / Sales3.5×4.2×9th cheapest of 21
Growth the price implies (Req g, 7 yrs)8.9%-0.3%3rd most demanding of 9
Growth delivered (Del g)+9.1%+3.9%2nd highest of 9
Hurdle (Req g minus delivered)-0.2 pp-0.1 pp5th least demanding of 9
ROIC minus cost of capital+4.9 pp-3.0 pp5th highest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Newland Pharmaceutical 301277.SZChina$488M-22%+9%11%3.5×8.9%+9.1%
Nanjing Hicin Pharmaceutical 300584.SZChina$487M-29%+32%17%4.3×3.3%-1.1%
Hefei Lifeon Pharmaceutical 003020.SZChina$486M-21%-1%10%2.0×n/an/a
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Shanghai MicuRx Pharmaceutical 688373.SSChina$481M-8%+23%-61%19.0×n/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
REGENXBIO RGNXUnited States$480M+22%-5%-120%3.1×n/an/a
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Hansa Biopharma HNSA.STSweden$479M+39%+69%-190%14.9×-4.7%+105.3%
Shanghai Fudan Forward S&T 600624.SSChina$478M0%-14%-34%6.4×n/an/a
SMS Pharmaceuticals SMSPHARMA.NSIndia$477M+16%+13%16%4.9×n/an/a
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Aquestive Therapeutics AQSTUnited States$475M-9%+13%-114%10.9×n/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
YungShin Global 3705.TWTaiwan$472M+5%-5%15%2.0×-3.8%+0.7%
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
ChengDa PharmaCeuticals 301201.SZChina$472M-47%+27%-9%4.8×n/an/a

Questions

Which companies are Newland Pharmaceutical's closest peers?
The cockpit's peer set: Nanjing Hicin Pharmaceutical (300584.SZ), Hefei Lifeon Pharmaceutical (003020.SZ), Tong Ren Tang Technologies (1666.HK), Shandong Wohua Pharmaceutical (002107.SZ), Aarti Drugs (AARTIDRUGS.NS), Shanghai MicuRx Pharmaceutical (688373.SS), Daewoong (003090.KS), Jiangsu Lianhuan Pharmaceutical (600513.SS).
Is Newland Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 3.5× against a peer median of 4.2×, 9th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -0 pp: the price already allows for a slowdown.
How has Newland Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -22.5% against -13.3% for the median peer; over one year -36.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.